Archive for the ‘Ardes Biosciences Inc’ Category

Ardes Biosciences Inc

January 11th, 2011 | Posted in 2011, Ardes Biosciences Inc

Ardes Biosciences Inc., has announced that it has earned a $15-million milestone payment from Bayer HealthCare AG under the terms of their 4/09 global license agreement to development and commercialize Ardea’s mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications.  This milestone payment was triggered by the initiation of a Phase 2 clinical […]